Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plasmodium immunotherapy - CAS Lamvac Biotech

Next Previous
X
Search
Drug Profile

Plasmodium immunotherapy - CAS Lamvac Biotech

Alternative Names: Plasmodium cancer vaccine - CAS Lamvac Biotech; Plasmodium immunotherapy for cancer

Latest Information Update: 18 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Developer CAS Lamvac Biotech; State Key Laboratory of Respiratory Disease
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 07 Jul 2023 CAS Lamvac Biotech and The Third Affiliated Hospital of Southern Medical University plan a phase II/III trial for Liver cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral), in August 2023 , (NCT05924776)
  • 24 Oct 2019 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT04165590)
  • 01 Jan 2018 Phase-I/II clinical trials in Breast cancer (Late-stage disease) in China (Parenteral) (ChiCTR1800015253)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top